CN113599475A - 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 - Google Patents
一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN113599475A CN113599475A CN202111041115.1A CN202111041115A CN113599475A CN 113599475 A CN113599475 A CN 113599475A CN 202111041115 A CN202111041115 A CN 202111041115A CN 113599475 A CN113599475 A CN 113599475A
- Authority
- CN
- China
- Prior art keywords
- parts
- warming
- fructus
- kidney
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 65
- 238000010792 warming Methods 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 210000003734 kidney Anatomy 0.000 claims abstract description 34
- 241000132012 Atractylodes Species 0.000 claims abstract description 16
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 14
- 244000268590 Euryale ferox Species 0.000 claims abstract description 14
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 11
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 11
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 11
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 11
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract description 5
- 235000005300 cardamomo Nutrition 0.000 claims abstract description 5
- 241000173529 Aconitum napellus Species 0.000 claims abstract 2
- 230000012173 estrus Effects 0.000 claims description 35
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 20
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 20
- 229940040129 luteinizing hormone Drugs 0.000 claims description 20
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 18
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 18
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 12
- 235000008397 ginger Nutrition 0.000 claims description 12
- 229940088597 hormone Drugs 0.000 claims description 12
- 239000005556 hormone Substances 0.000 claims description 12
- 241000045403 Astragalus propinquus Species 0.000 claims description 11
- 235000008184 Piper nigrum Nutrition 0.000 claims description 11
- 244000203593 Piper nigrum Species 0.000 claims description 11
- 235000013614 black pepper Nutrition 0.000 claims description 11
- 239000001931 piper nigrum l. white Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000262 estrogen Substances 0.000 claims description 9
- 229940011871 estrogen Drugs 0.000 claims description 9
- 208000000509 infertility Diseases 0.000 claims description 7
- 231100000535 infertility Toxicity 0.000 claims description 7
- 230000036512 infertility Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 241000112528 Ligusticum striatum Species 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 229940010454 licorice Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 3
- 206010058314 Dysplasia Diseases 0.000 claims description 3
- 208000011707 Ovulation disease Diseases 0.000 claims description 3
- 244000236658 Paeonia lactiflora Species 0.000 claims description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 3
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 244000050907 Hedychium coronarium Species 0.000 claims 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 10
- 210000004291 uterus Anatomy 0.000 abstract description 8
- 230000016087 ovulation Effects 0.000 abstract description 7
- 230000005906 menstruation Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 6
- 230000008217 follicular development Effects 0.000 abstract description 4
- 230000035800 maturation Effects 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 230000035935 pregnancy Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 description 14
- 241000227129 Aconitum Species 0.000 description 13
- 241000234314 Zingiber Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 9
- 235000011477 liquorice Nutrition 0.000 description 9
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 241001346334 Amomum tsao-ko Species 0.000 description 7
- 201000010066 hyperandrogenism Diseases 0.000 description 7
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 7
- 229960003881 letrozole Drugs 0.000 description 7
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 6
- 210000004246 corpus luteum Anatomy 0.000 description 6
- 241000382455 Angelica sinensis Species 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 description 5
- 241001106477 Paeoniaceae Species 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229960003105 metformin Drugs 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000003098 androgen Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000031877 prophase Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010002659 Anovulatory cycle Diseases 0.000 description 3
- 230000031016 anaphase Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 241000010428 Alpinia katsumadae Species 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- 241000212322 Levisticum officinale Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000013230 female C57BL/6J mice Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000001645 levisticum officinale Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用,属于医药技术领域。本发明提供的治疗多囊卵巢综合征的温中补肾组合物,包括党参、黄芪、山药、白术、茯苓、莲子、芡实、补骨脂、砂仁、草寇、茴香、肉桂、吴茱萸、黑附子。本发明以温中健脾为重点,佐以温肾助阳、活血通经,诸药合用,共奏补气健脾,温肾助阳,温经散寒,养血祛瘀,调节冲任、暖胞宫之效,从而促进卵泡发育、成熟,排卵受孕,治疗多囊卵巢综合征的临床有效率达到80%以上。
Description
技术领域
本发明属于医药技术领域,尤其涉及一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用。
背景技术
根据世卫组织的定义和数据,不孕不育被定义为一种会导致残疾的疾病,在全球最严重的残疾中排名第五。而多囊卵巢综合征(Polycystic ovarian syndrome,PCOS)是导致妇女排卵障碍性不孕中最常见的原因。约90%的PCOS患者伴有不孕,排卵障碍性不孕妇女中有80%由PCOS引起。而且近年来,多囊卵巢综合征的发病率有逐步上升的趋势,严重影响了人们的生理和心理健康,降低了人们的幸福感。
PCOS是常见的内分泌疾病,其发生率约占育龄女性6%~10%,以雄激素过高、持续无排卵、卵巢多囊样改变为特征,常伴有胰岛素抵抗和肥胖,临床表现为不孕、闭经、肥胖、痤疮、月经稀发、高雄激素症、高胰岛素血症等。目前治疗PCOS的方法有很多,例如西医主要依靠周期性激素替代疗法、手术和腹腔镜下电灼等方法治疗,疗效显著,但易导致增加多卵泡和卵巢过激综合征及黄体缺陷的风险,而且手术治疗成本高、风险大、损伤性严重。因此,近年来许多国内外学者纷纷致力于寻找一种安全有效的替代方法,使治疗PCOS的副作用能够降到最低。
在中医的整体观念和辨证论治指导下,中药方剂的多系统、多环节、多靶点作用的优势逐渐凸显出来,但是目前尚未公开一种在临床上治疗PCOS效果突出的温中补肾中药方剂。
发明内容
有鉴于此,本发明的目的在于提供一种在临床上治疗PCOS效果突出的温中补肾中药方剂,以温中健脾为重点,佐以温肾助阳、活血通经,诸药合用,共奏补气健脾,温肾助阳,温经散寒,养血祛瘀,调节冲任、暖胞宫之效,从而促进卵泡发育、成熟,排卵受孕,治疗PCOS的临床有效率达到80%以上。
为了实现上述发明目的,本发明提供了以下技术方案:
本发明提供了一种治疗多囊卵巢综合征的温中补肾组合物,所述组合物包括如下组分:党参、黄芪、山药、白术、茯苓、莲子、芡实、补骨脂、砂仁、草寇、茴香、肉桂、吴茱萸、黑附子。
优选的,所述组合物还包括当归、白芍、川芎、白胡椒、生姜和甘草中的一种或多种。
优选的,所述黄芪为炙黄芪,所述山药为麸炒山药,所述白术为麸炒白术,所述补骨脂为盐炙补骨脂,所述草寇为姜草寇,所述吴茱萸为制吴茱萸,所述黑附子为制黑附子,所述甘草为炙甘草。
优选的,所述组合物包括按照重量份数计的如下组分:党参15-30份、黄芪20-40份、山药15-30份、白术5-20份、茯苓6-20份、莲子6-20份、芡实6-20份、补骨脂8-20份、砂仁3-10份、草寇8-20份、茴香10-30份、肉桂6-20份、吴茱萸6-20份、黑附子3-20份。
本发明还提供了一种上述组合物的制备方法,包括如下步骤:将各组分混合后,用水煎煮。
本发明还提供了一种上述组合物在制备治疗多囊卵巢综合征产品中的应用。
本发明还提供了一种上述组合物在制备改善体重异常和糖耐量异常产品中的应用。
本发明还提供了一种上述组合物在制备治疗多囊卵巢综合征所致的动情周期紊乱、卵泡发育异常、排卵障碍和不孕产品中的应用。
本发明还提供了一种上述组合物在制备治疗多囊卵巢综合征所致的激素紊乱产品中的应用,所述激素包括但不限于雄睾酮激素、雌激素、性激素结合球蛋白、黄体生成素、卵泡刺激素。
优选的,上述产品包括药品、食品。
本发明的有益效果:
本领域对于PCOS的治疗均重在补肾,而本发明以温中健脾为重点,佐以温肾助阳、活血通经,诸药合用,共奏补气健脾,温肾助阳,温经散寒,养血祛瘀,调节冲任、暖胞宫之效,从而促进卵泡发育、成熟,排卵受孕,对多囊卵巢综合征的临床治疗有效率达到80%以上。
另外,本发明所述温中补肾方不仅可以治疗PCOS引起的卵巢多囊、动情周期紊乱,还可以有效改善PCOS所致的体重和糖耐量水平异常、减轻PCOS,为有效临床治疗PCOS提供了新的思路和理论基础。
附图说明
图1 H&E染色技术检测各组卵巢形态学改变,放大倍数10X;
图2温中补肾方对激素的影响,A:睾酮激素(T)水平,B:雌激素(E2)水平,C:性激素结合球蛋白(SHBG),D:黄体生成素(LH)水平,E:卵泡刺激素(FSH)水平,F:黄体生成素与卵泡刺激素比值(LH/FSH),
(*P<0.05,**P<0.01,***P<0.0005与空白正常组比较;#p<0.05,##p<0.01,###<0.0005与PCOS模型组比较);
图3温中补肾方治疗PCOS所致的动情周期紊乱,其中A为空白对照组(正常组)动情周期各阶段H&E染色(放大倍数20X),B为不同组别动情周期各阶段占总动情周期的百分比;
图4温中补肾方改善PCOS体重及糖耐量(OGTT),其中A为体重指数(BMI);B为治疗前口服葡萄糖耐量分为正常组和模型组;C为治疗前糖耐量曲线下面积(AUC);D为治疗后口服葡萄糖耐量;E为治疗后糖耐量曲线下面积(AUC);(*P<0.05,**P<0.01,***P<0.001与control组比较;#p<0.05,##p<0.01,###<0.001与model组比较)。
具体实施方式
本发明提供了一种治疗多囊卵巢综合征的温中补肾组合物,所述组合物包括如下组分:党参、黄芪、山药、白术、茯苓、莲子、芡实、补骨脂、砂仁、草寇、茴香、肉桂、吴茱萸、黑附子。
本发明对于上述各组分药味的具体来源没有特殊限定,采用本领域常规市售产品均可。在本发明中,所述组合物优选的还包括当归、白芍、川芎、白胡椒、生姜和甘草中的一种或多种。
本发明提出PCOS为脾胃虚寒,冲任失调所致,冲为血海,任主胞胎,二脉皆起于胞宫,循行于少腹,与经、产关系密切。脾胃为营卫气血生化之源,脾胃气虚,纳运乏力,无法化生气血,故而月经后期甚至闭经等;冲任虚寒,血凝气滞,故少腹里急、腹满、月经不调、甚或久不受孕;若瘀血阻滞,血不循经,加之冲任不固,则月经先期、或一月再行,甚或崩中漏下;若寒凝血瘀,经脉不畅,则致痛经;瘀血不去,新血不生,不能濡润,故唇口干燥。本发明方证虽属瘀、寒、虚、热错杂,然以冲任虚寒,瘀血阻滞为主,治当补气健脾、温经散寒、祛瘀养血之法。方中黄芪、党参益气健脾,以资生化之源,阳生阴长,气旺血充为君药。山药、白术、茯苓、甘草补气健脾,吴茱萸、肉桂、茴香、黑附子、砂仁、草寇,温经散寒,温肾助阳,通利血脉,补骨脂、莲子、芡实三药合用有益肾固精、补脾、养心安神的功效,共为臣药。当归、川芎活血祛瘀,养血调经共为佐药。白芍酸苦微寒,养血敛阴,柔肝止痛,并制吴茱萸、肉桂等之温燥。白胡椒、生姜辛开散结,通降胃气,以助祛瘀调经;其中生姜又温胃气以助生化,且助吴茱萸、肉桂等以温经散寒,以上均为佐药。甘草尚能调和诸药,兼为使药。诸药合用,共奏补气健脾,温肾助阳,温经散寒,养血祛瘀,调节冲任、暖胞宫从而促进卵泡发育、成熟,排卵受孕。
在本发明中,所述山药优选为麸炒山药,所述白术优选为麸炒白术,所述补骨脂优选为盐炙补骨脂,所述草寇优选为姜草寇,所述吴茱萸优选为制吴茱萸,所述黑附子优选为制黑附子,所述甘草优选为炙甘草。本发明对于上述各药味的炮制工艺具体参数等没有特殊要求,采用本领域常规制备麸炒山药、麸炒白术、盐炙补骨脂、姜草寇、制吴茱萸、制黑附子、炙甘草的方法即可。
在本发明中,所述组合物优选的包括按照重量份数计的如下组分:党参15-30份、黄芪20-40份、山药15-30份、白术5-20份、茯苓6-20份、莲子6-20份、芡实6-20份、补骨脂8-20份、砂仁3-10份、草寇8-20份、茴香10-30份、肉桂6-20份、吴茱萸6-20份、黑附子3-20份。当所述组合物还包括当归、白芍、川芎、白胡椒、生姜和甘草时,所述组合物各组分的重量份数优选为党参15-30份、黄芪20-40份、山药15-30份、当归10-30份、白术5-20份、茯苓6-20份、白芍6-20份、川芎8-20份、莲子6-20份、芡实6-20份、补骨脂8-20份、砂仁3-10份、草寇8-20份、茴香10-30份、肉桂6-20份、吴茱萸6-20份、白胡椒6-20份、生姜6-20份、黑附子3-20份、甘草6-20份,更优选为:党参18-25份、黄芪25-35份、山药18-25份、当归15-25份、白术8-15份、茯苓9-15份、白芍8-15份、川芎9-15份、莲子8-15份、芡实9-15份、补骨脂9-15份、砂仁4-8份、草寇9-15份、茴香15-25份、肉桂9-15份、吴茱萸8-15份、白胡椒8-15份、生姜8-15份、黑附子8-15份、甘草9-15份。
本发明还提供了一种上述组合物的制备方法,包括如下步骤:将各组分混合后,用水煎煮。
本发明对于上述各组分的来源没有特殊限定,采用本领域常规市售产品均可,如可直接购买上述各组分饮片、根块、叶子、粉碎颗粒,混合后,水煎煮即可。本发明对于煎煮所用的水的来源没有特殊限定,采用本领域常规饮用水均可。在本发明中,所述水的用量优选为各组分用量总和的1-3倍,更优选为各组分用量总和的2倍。本发明对于煎煮的具体方式没有特殊限定,所述煎煮的时间优选为30min-1h,更优选为30min-50min。在本发明具体实施例中,采用大火煮沸后,小火煎煮的方式。按照本发明的制备方法获得水煎剂后,一日一剂,早晚或早中晚饭后分服。
本发明还提供了一种上述组合物在制备治疗多囊卵巢综合征、改善体重异常和糖耐量异常、治疗多囊卵巢综合征所致的动情周期紊乱、卵泡发育异常、排卵障碍和不孕、多囊卵巢综合征所致的激素紊乱产品中的应用。
在本发明中,所述激素包括但不限于雄睾酮激素(T)、雌激素(E2)、性激素结合球蛋白(SHBG)、黄体生成素(LH)水平、卵泡刺激素(FSH)。优选的,本发明所述组合物还能治疗多囊卵巢综合征所致的黄体生成素与卵泡刺激素比值(LH/FSH)异常。
在本发明中,所述产品优选的包括药品、食品。
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
本发明运用SPSS 22.0统计分析软件对所得数据进行统计,计数资料用卡方检验;计量资料用均数±标准差表示。多个样本均数间比较采用完全随机设计资料的单因素方差分析(One-WayANOVA),多个样本均数之间的多重比较采用LSD-t检验,组间比较经方差齐性检验后采用成组t检验;当各组方差不齐时用Dunnett法进行均数间的两两比较,检验水准为α=0.05。
实施例1
准确称取生党参20g、炙黄芪30g、麸炒山药20g、生当归20g、麸炒白术10g、生茯苓10g、生白芍10g、生川芎10g、莲子肉10g、生芡实10g、盐炙补骨脂10g、生砂仁5g、姜草寇10g、生茴香20g、生肉桂10g、制吴茱萸10g、白胡椒10g、生姜10g、制黑附子10g、炙甘草10g(上述各组分均为市售购买的颗粒),混合后,添加510g水,大火煮沸后,小火煎煮30min,即得。
实施例2
准确称取党参15g、黄芪20g、山药15g、当归10g、白术5g、茯苓6g、、、莲子6g、芡实6g、补骨脂8g、砂仁3g、草寇8g、茴香10g、肉桂6g、吴茱萸6g、白胡椒6g、黑附子3g、甘草6g,混合后,加447g水,大火煮沸后,小火煎煮1h,即得。
实施例3
准确称取党参30g、黄芪40g、山药30g、当归30g、白术20g、茯苓20g、川芎20g、莲子20g、芡实20g、补骨脂20g、砂仁10g、草寇20g、茴香30g、肉桂20g、吴茱萸20g、白胡椒20g、生姜20g、黑附子20g、甘草20g,混合后,加900g水,大火煮沸后,小火煎煮50min,即得。
实施例4
准确称取党参25g、黄芪35g、山药25g、白术15g、茯苓15g、白芍15g、川芎15g、莲子15g、芡实15g、补骨脂15g、砂仁8g、草寇15g、茴香25g、肉桂15g、吴茱萸15g、白胡椒15g、生姜15g、黑附子15g、甘草15g,混合后,加330g水,大火煮沸后,小火煎煮40min,即得。
实施例5
本发明温中补肾方可以治疗PCOS小鼠卵巢组织病变
来曲唑1mg/kg/d联合高脂灌胃4周龄雌性C57BL/6J小鼠21天,构建PCOS模型。镜下观察PCOS模型小鼠卵巢明显多囊,几乎看不见卵泡和黄体,也未见卵母细胞,大多数卵泡严重闭锁,闭锁卵泡直径增大。颗粒细胞层受到挤压,排列稀疏,甚至消失,表明建模成功。
将实施例1中各组分及颗粒的混合物加生理盐水配置成浓度为1g/ml的药液,储存在4℃下待用。中药组根据实验动物等效计量的研究方法,按“人与动物体表面积折算的等效剂量比值表”,由人换算成小鼠的剂量为中剂量即2g/kg/d,高剂量为中剂量的两倍即4g/kg/d。将PCOS模型小鼠平均分成四组,每组6只,其中模型组灌胃给予来曲唑1mg/kg/d,中剂量组按灌药量2g/kg/d灌胃给予本发明温中补肾方剂,高剂量组按灌药量4g/kg/d灌胃给予本发明温中补肾方剂,阳性对照组给予二甲双胍200mg/kg/d灌胃,选取未进行建模处理的4周龄雌性C57BL/6J小鼠6只,作为空白对照组(正常组),生理盐水灌胃200μl/只/天,30天后,处死小鼠,取卵巢组织,分别进行H&E染色,结果如图1所示。
由图1可以看出,正常对照组小鼠的卵巢在H&E染色下可见多个不同发育阶段的卵泡及黄体,颗粒细胞形态完整且排列整齐。模型组小鼠,卵巢明显表现为多囊、卵泡和黄体看不见,也没有发现卵母细胞,大多数卵泡严重闭锁,闭锁卵泡的直径增大,此外,颗粒细胞层被挤压和稀疏排列,甚至消失。温中补肾方组小鼠闭锁卵泡的数量显著减少,次级卵泡的数量增加,卵巢内均可见黄体和多个不同发育阶段的卵泡,接近成熟期的卵泡可见卵细胞及放射冠,颗粒细胞层增厚并紧密聚集,形态接近正常对照组及阳性对照组,尤其是高剂量组,效果明显。
将实施例2中各组分及颗粒的混合物重复进行上述实验,得到与实施例1相似的结果。
实施例6
本发明温中补肾方可以改善PCOS激素紊乱,降低雄激素(睾酮T)水平,恢复雌激素E2、黄体生成素(LH)、卵泡刺激素(FSH)及性激素结合球蛋白(SHBG)稳态。
高雄激素血症和性激素紊乱是PCOS主要特征。PCOS小鼠模型的构建以及分组处理的方式均同实施例5,30天后,取各组小鼠血清进行血清雄激素、雌激素E2、黄体生成素(LH)、卵泡刺激素(FSH)及性激素结合球蛋白(SHBG)检测,结果如图2所示。血清性激素检测结果显示,与正常组小鼠相比,PCOS模型组的血清睾酮T、LH和LH/FSH水平显著升高。(图2A、D、F)、雌激素(E2)和性激素结合球蛋白(SHBG)的水平也明显低于其他组(图2B、C),温中补肾方及二甲双胍治疗后T、LH和LH/FSH水平显著下降,E2和SHBG水平显著升高。
由图2可以看出,与正常组小鼠相比,PCOS模型组小鼠血清雄激素(T)水平明显增高,雌激素E2、黄体生成素(LH)、卵泡刺激素(FSH)及性激素结合球蛋白(SHBG)等激素紊乱,亦进一步证实本发明造模方法造模成功。而采用本发明温中补肾方治疗后,各激素水平显著恢复稳态,证实本发明温中补肾方可以改善PCOS激素紊乱。
实施例7
本发明温中补肾方可以治疗PCOS所致的动情周期紊乱
动情周期是指雌性哺乳动物从上一次发情开始至下一次发情开始,或指上一次排卵至下一次排卵之间的时间间隔。通常根据动物的精神状态、雌性动物对雄性动物产生的性欲表现、卵巢内卵泡的生长发育、排卵和黄体形成的情况及雌性生殖道(子宫、阴道等)的生理变化等几个主要方面,将动情周期划分为动情前期(前情期)、动情期、动情后期(后情期)及间情期(间期)。在动情周期中卵巢、子宫与阴道等主要附属性器官也处于不断变化。拥有规律的动情周期是哺乳动物性成熟的标志,意味着卵巢开始发挥功能。
PCOS小鼠模型的构建以及分组处理的方式均同实施例5,从造模开始,每3天用阴道脱落细胞冲洗液涂片法检测动情周期并记录各组小鼠动情周期变化,直至造模成功后第30天处死小鼠。具体检测步骤为:用滴管吸取适量生理盐水,每3天,在同一时间点冲洗、吸取阴道分泌物于载玻片上,迅速于显微镜下观察细胞形态,判断动情周期。空白对照组(正常组)结果如图3A所示。由图3A可以看出,动情间期可见大量白细胞,极少量梭形上皮细胞。动情前期可见成群或单独出现的梭形上皮细胞,白细胞较少。动情期见大量角化细胞,形状大而不规则,无核,白细胞消失。动情后期可见多种细胞类型,白细胞,无核的上皮细胞及梭形上皮细胞。
通过对每组连续的动情周期的检测和记录,本发明做了动情周期各阶段占总动情周期的百分比,如图3B所示。由图3B可以看出,空白对照组小鼠阴道涂片观察动情周期规则,呈现动情前期、动情期、动情后期、动情间期,4-5d为一性周期且规律出现。
对模型组、二甲双胍组、温中补肾方中剂量组和高剂量组小鼠阴道涂片观察发现脱落细胞持续白细胞,失去正常动情周期。而治疗后,二甲双胍组、温中补肾方中剂量组和高剂量组小鼠由刚开始持续的间期,逐渐出现动情前期、动情期、动情后期,间期的循环变化,且随着治疗越来越有规律。由此可见,二甲双胍组及温中补肾方中剂量组和高剂量组对PCOS小鼠的发情周期具有调节作用。此外,在中剂量和高剂量组中,高剂量对PCOS小鼠发情周期的恢复率可达80%,表明本发明温中补肾方可以调节PCOS所致发情周期。
实施例8
温中补肾方可以改善PCOS体重及糖耐量(OGTT)
PCOS临床上常伴有体重、血糖血脂异常,PCOS患者是发生代谢综合征的高危人群,其高体重,糖耐量减低和糖尿病的发生率明显高于普通女性群体。
明确高脂喂养及来曲唑能诱导PCOS小鼠胰岛素抵抗和高雄激素血症:
来曲唑是芳香化酶抑制剂,可以抑制卵巢雄激素向雌激素的转化,从而造成高雄激素血症。高脂喂养可以造成胰岛素抵抗。高脂喂养加灌胃给来曲唑,1mg/kg/d,连续21天可以造成胰岛素抵抗及高雄激素血症的PCOS模型。
将4周龄的C57BL/6J雌性小鼠随机分为2组,一组6只,给予正常饲料喂养为正常组(control),另外一组24只,给予高脂饲料喂养(HFD),HFD组分别分为四组:一组持续给予HFD饲养,剩下三组同时灌胃给予来曲唑(芳香化酶抑制剂)21天,期间每天检测小鼠体重、摄食,并在第20天给予口服葡萄糖耐量(OGTT)实验,第21天给予胰岛素耐量实验(ITT),验证PCOS模型胰岛素抵抗和高雄激素血症的成功建立。
将构建成功的PCOS小鼠模型进行分组,平均分为模型组(model组)灌胃给予来曲唑1mg/kg/d,阳性对照组(MET组)给予二甲双胍200mg/kg/d灌胃,中剂量组按灌药量2g/kg/d灌胃给予本发明温中补肾方剂,高剂量组按灌药量4g/kg/d灌胃给予本发明温中补肾方剂灌胃给予本发明温中补肾方剂(其中温中补肾方剂的处理方式同实施例5)。所有小鼠,从造模开始,每3天检测并记录各组小鼠体重、摄食、治疗第28天给予口服葡萄糖耐量(OGTT)实验,治疗第30天处死小鼠。
结果如图4所示。由图4可以看出,与正常组相比,PCOS模型(Model组)组体重指数BMI((末体重-初体重)/初体重×100%)明显增高(见图A),口服糖耐量试验(OGTT)明显升高恶化(图B),而治疗后二甲双胍(MET)组及温中补肾方中剂量、高剂量组有明显降低的作用(图D),而且其对应的曲线下面积AUC(图C、E)更清楚表达了各组的关系。结果表明本发明温中补肾方可以调节PCOS小鼠的体重及糖耐量水平,从而改善PCOS。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种治疗多囊卵巢综合征的温中补肾组合物,其特征在于,所述组合物包括如下组分:党参、黄芪、山药、白术、茯苓、莲子、芡实、补骨脂、砂仁、草寇、茴香、肉桂、吴茱萸、黑附子。
2.根据权利要求1所述的组合物,其特征在于,所述组合物还包括当归、白芍、川芎、白胡椒、生姜和甘草中的一种或多种。
3.根据权利要求1所述的组合物,其特征在于,所述黄芪为炙黄芪,所述山药为麸炒山药,所述白术为麸炒白术,所述补骨脂为盐炙补骨脂,所述草寇为姜草寇,所述吴茱萸为制吴茱萸,所述黑附子为制黑附子,所述甘草为炙甘草。
4.根据权利要求1所述的组合物,其特征在于,所述组合物包括按照重量份数计的如下组分:党参15-30份、黄芪20-40份、山药15-30份、白术5-20份、茯苓6-20份、莲子6-20份、芡实6-20份、补骨脂8-20份、砂仁3-10份、草寇8-20份、茴香10-30份、肉桂6-20份、吴茱萸6-20份、黑附子3-20份。
5.一种权利要求1-4任意一项所述组合物的制备方法,其特征在于,包括如下步骤:将各组分混合后,用水煎煮。
6.权利要求1-4任意一项所述组合物在制备治疗多囊卵巢综合征产品中的应用。
7.权利要求1-4任意一项所述组合物在制备改善体重异常和糖耐量异常产品中的应用。
8.权利要求1-4任意一项所述组合物在制备治疗多囊卵巢综合征所致的动情周期紊乱、卵泡发育异常、排卵障碍和不孕产品中的应用。
9.权利要求1-4任意一项所述组合物在制备治疗多囊卵巢综合征所致的激素紊乱产品中的应用,其特征在于,所述激素包括但不限于雄睾酮激素、雌激素、性激素结合球蛋白、黄体生成素、卵泡刺激素。
10.根据权利要求6-9任意一项所述的应用,其特征在于,所述产品包括药品、食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111041115.1A CN113599475B (zh) | 2021-09-07 | 2021-09-07 | 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111041115.1A CN113599475B (zh) | 2021-09-07 | 2021-09-07 | 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113599475A true CN113599475A (zh) | 2021-11-05 |
CN113599475B CN113599475B (zh) | 2022-07-12 |
Family
ID=78342707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111041115.1A Active CN113599475B (zh) | 2021-09-07 | 2021-09-07 | 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113599475B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116392567A (zh) * | 2023-03-29 | 2023-07-07 | 宁夏医科大学 | 一种改善睾丸功能障碍的中药组合物及其制备方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102205030A (zh) * | 2011-05-04 | 2011-10-05 | 李云萍 | 一种治疗多囊卵巢综合症的中药益坤调经汤 |
CN103055242A (zh) * | 2012-12-31 | 2013-04-24 | 彭少芳 | 一种改善体质固肾育胎的中药制剂 |
CN105596495A (zh) * | 2016-01-06 | 2016-05-25 | 侯丽辉 | 治疗青春期多囊卵巢综合征的中药复方 |
CN107661471A (zh) * | 2017-09-29 | 2018-02-06 | 曹秀娟 | 一种治疗女性不孕症的中药配方及其制备方法 |
CN108324821A (zh) * | 2018-04-19 | 2018-07-27 | 山东中医药大学 | 一种具有诱发卵泡发育作用的中药组合物及其应用 |
CN109200162A (zh) * | 2018-11-27 | 2019-01-15 | 长春中医药大学 | 一种治疗多囊卵巢综合征的中药制剂及制备方法 |
CN112891490A (zh) * | 2021-03-02 | 2021-06-04 | 安徽医科大学 | 一种用于治疗不孕症的药物及其制备方法、应用 |
-
2021
- 2021-09-07 CN CN202111041115.1A patent/CN113599475B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102205030A (zh) * | 2011-05-04 | 2011-10-05 | 李云萍 | 一种治疗多囊卵巢综合症的中药益坤调经汤 |
CN103055242A (zh) * | 2012-12-31 | 2013-04-24 | 彭少芳 | 一种改善体质固肾育胎的中药制剂 |
CN105596495A (zh) * | 2016-01-06 | 2016-05-25 | 侯丽辉 | 治疗青春期多囊卵巢综合征的中药复方 |
CN107661471A (zh) * | 2017-09-29 | 2018-02-06 | 曹秀娟 | 一种治疗女性不孕症的中药配方及其制备方法 |
CN108324821A (zh) * | 2018-04-19 | 2018-07-27 | 山东中医药大学 | 一种具有诱发卵泡发育作用的中药组合物及其应用 |
CN109200162A (zh) * | 2018-11-27 | 2019-01-15 | 长春中医药大学 | 一种治疗多囊卵巢综合征的中药制剂及制备方法 |
CN112891490A (zh) * | 2021-03-02 | 2021-06-04 | 安徽医科大学 | 一种用于治疗不孕症的药物及其制备方法、应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116392567A (zh) * | 2023-03-29 | 2023-07-07 | 宁夏医科大学 | 一种改善睾丸功能障碍的中药组合物及其制备方法和应用 |
CN116392567B (zh) * | 2023-03-29 | 2024-03-08 | 宁夏医科大学 | 一种改善睾丸功能障碍的中药组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113599475B (zh) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104984297A (zh) | 一种药物组合物在制备治疗闭经药物中的用途 | |
CN104162094A (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN109528980B (zh) | 一种用于治疗卵巢储备功能下降疾病的中药组合物及其制药应用 | |
CN104922613A (zh) | 一种治疗不孕不育症的药物组合物及其制备方法 | |
CN113599475B (zh) | 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 | |
CN104491802A (zh) | 一种中药制剂在制备治疗急慢性胃炎药物中的用途 | |
CN116763888A (zh) | 一种改善控制性超促排卵周期卵泡发育和卵子质量的中药组合物及其应用 | |
CN114177256B (zh) | 一种治疗卵巢储备功能减退的中药组合物及其应用 | |
CN101664533B (zh) | 一种治疗急慢性乳腺增生的中药及制备方法 | |
CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
CN103285284B (zh) | 一种治疗老年性阴道炎的药物组合物 | |
CN103301353B (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN105944020B (zh) | 一种治疗卵巢功能下降的中药 | |
CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
CN110201122B (zh) | 一种治疗月经不调的中药组合物及其制备方法和用途 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN105288538A (zh) | 一种药物组合物用于制备治疗闭经药物中的用途 | |
CN105497262A (zh) | 一种治疗肝肾阴虚型多囊卵巢综合征的药物组合物 | |
CN105362629A (zh) | 一种含有杜仲的治疗女性更年期综合症的药物组合物及其制备方法 | |
CN109985125B (zh) | 一种助孕口服液及其制备方法 | |
CN112656867B (zh) | 一种治疗异常子宫出血的中药组合物及其制备方法 | |
CN106540168B (zh) | 一种治疗肾虚型月经不调、闭经及不孕症的中药组合物及制备方法、应用 | |
CN105727237A (zh) | 一种含艾叶的治疗闭经的药物组合物 | |
CN100998743A (zh) | 一种治疗妇女不孕不育症的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |